Patents by Inventor Tamás Bíró

Tamás Bíró has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11413266
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 16, 2022
    Assignee: GW Pharma Limited
    Inventors: Tamás Biró, Colin Stott, Vincenzo Di Marzo
  • Publication number: 20220040125
    Abstract: The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Tamas Biro, Ethan B. Russo
  • Patent number: 11154515
    Abstract: The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 26, 2021
    Assignee: Phytecs, Inc.
    Inventors: Tamas Biro, Ethan B. Russo
  • Publication number: 20200093755
    Abstract: The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Inventors: Tamas Biro, Ethan B. Russo
  • Publication number: 20180263952
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: GW Pharma Limited
    Inventors: Tamás Bíró, Colin Stott, Vincenzo Di Marzo
  • Publication number: 20130195830
    Abstract: The subject of the invention is a perorally applicable preparation of vegetable origin, resistant to pepsin and trypsin, based on histaminase, optionally for the use as an agent for improving digestion, reducing appetite or reducing body weight. The preparation of the invention is a pressed juice—which is optionally in lyophilized form—obtained from seedlings of pea (Pisum sativum L.), lentil (Lens culinaris), chick pea (Cicer arietinum), grass pea (Latirus sativus), bean (Phaseolus vulgaris) or field bean (Vicia faba) or—from a mixture of seedlings of the above mentioned plants—which contains histaminase, catalase and protease inhibitor. The subject as well of the invention is the production of the above preparation.
    Type: Application
    Filed: September 2, 2010
    Publication date: August 1, 2013
    Applicant: DEBRECENI EGYETEM
    Inventors: Sándor Sipka, Zoltán Györy, Jánosné Borbély, Tamás Keresztes, Péter Várnai, Tamás Bíró